<?xml version="1.0" encoding="UTF-8"?>
<p id="Par11">G-CSF was given to all patients since day +5 until neutrophil recovery. All patients received prophylactic levofloxacin, acyclovir from the beginning of conditioning therapy until hematological reconstitution. Prophylactic posaconzale was administered from the day of the conditioning until 1 month after transplant [
 <xref ref-type="bibr" rid="CR11">11</xref>]. Quantitative real-time PCR assays for CMV DNA in serum and EBV DNA in whole blood were performed once or twice per week. Preemptive therapy with ganciclovir (5 mg/kg, twice) started if CMV DNA was more than 1000 copies/ml. Preemptive therapy with rituximab (a single dose 375 mg/m
 <sup>2</sup>) was initiated when EBV DNA increased a log or more within 1 week or above 1×10
 <sup>5</sup> copies/ml in high-risk patients [
 <xref ref-type="bibr" rid="CR12">12</xref>] with EBV reactivation. EBV-related posttransplant lymphoproliferative disease (PTLD) was treated with reducing dose of immunosuppressive agents (RIS) and rituximab once per week for maximum of four courses [
 <xref ref-type="bibr" rid="CR13">13</xref>].
</p>
